Ovarian cancer treatment has shifted dramatically over the past decade, moving from a one-size-fits-all reliance on surgery and platinum-based chemotherapy toward a more layered approach that includes targeted drugs, biomarker-guided decision-making, and novel surgical techniques. The most transformative development has been the introduction of PARP inhibitors as maintenance therapy, but advances in antibody-drug conjugates, anti-angiogenic agents, heated intraperitoneal chemotherapy, and liquid biopsy monitoring have each reshaped the treatment landscape in meaningful ways. Progress has been uneven across subtypes and patient populations, and drug resistance remains a persistent problem, but the direction of the field is clear.
PARP Inhibitors Changed the Standard of Care
For decades, the backbone of ovarian cancer treatment was surgery followed by platinum-taxane chemotherapy. While most patients initially responded, roughly 80% eventually developed resistance to platinum drugs after repeated treatment cycles, making recurrence almost inevitable in advanced disease.1PubMed Central. Role of the tumor microenvironment in chemotherapy resistance in ovarian cancer and targeted therapy PARP inhibitors upended this pattern by exploiting a specific vulnerability in tumor cells that have trouble repairing their own DNA.
The logic is straightforward in principle. Cells with mutations in BRCA1 or BRCA2 genes already have a broken DNA repair pathway. When a PARP inhibitor blocks a second repair pathway on top of that, the cancer cell accumulates so much DNA damage that it dies. This concept, called synthetic lethality, means the drug preferentially kills cancer cells while largely sparing normal ones.2PubMed Central. PARP inhibitors: Synthetic lethality in the clinic The effect has been confirmed repeatedly in BRCA-mutated ovarian cancers.3PubMed Central. Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells
Three PARP inhibitors, olaparib, niraparib, and rucaparib, have been approved in various settings for ovarian cancer. They are now used as maintenance therapy after a good response to platinum chemotherapy, where they can delay recurrence for months or even years. A large Cochrane review found that while PARP inhibitors significantly improved progression-free survival, they also increased the rate of severe side effects compared to placebo. Maintenance therapy roughly tripled the likelihood of a grade 3 or higher adverse event, though quality-of-life differences between PARP inhibitor and placebo arms were generally small and may not be clinically meaningful.4PubMed Central. Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
That tradeoff matters to patients in real terms. Women on PARP inhibitor maintenance describe their fatigue as milder than what they experienced during intravenous chemotherapy but consistently present. It limits daily activities, interferes with work, and disrupts family and social life. For many, it also chips away at their sense of identity and normalcy.5PubMed. Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study These lived experiences are worth weighing against the survival statistics, and they underscore why conversations between patients and oncologists about maintenance therapy should be open about what daily life on these drugs actually looks like.
How Doctors Decide Who Gets Which Drug
PARP inhibitors work best in patients whose tumors have defects in a DNA repair pathway known as homologous recombination. BRCA1 and BRCA2 mutations are the most well-known of these defects, but other genes can cause the same problem. Testing for a broader concept, homologous recombination deficiency (HRD), has become a key part of treatment planning. Validated HRD tests help predict who will benefit most from PARP inhibitors and can guide treatment selection in a more precise way than relying on BRCA status alone.6PubMed Central. Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
Genomic profiling has also revealed why some patients do better than others regardless of treatment. Long-term survivors of high-grade serous ovarian cancer tend to have tumors with a higher burden of mutations, frequent BRCA1/2 inactivation, and more active immune cells infiltrating the tumor. Short-term survivors, by contrast, are more likely to have tumors with certain copy number gains and low HRD scores, meaning their cancers are less amenable to drugs that exploit DNA repair weaknesses.7PubMed Central. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors This kind of molecular distinction is pushing the field toward more tailored strategies rather than treating all ovarian cancers the same way.
Resistance Remains the Central Challenge
For all the progress PARP inhibitors represent, resistance develops in a sizable proportion of patients. The mechanisms are varied and complex. The most common route is restoration of the very DNA repair pathway that the drug is supposed to exploit: cancer cells find workarounds that let them repair DNA again despite the drug’s interference. But other mechanisms also contribute, including reversion mutations that restore BRCA function, changes in how cells protect stalled DNA replication, alterations in drug transport that reduce how much of the drug reaches the cell, and epigenetic modifications that rewire gene activity.8PubMed Central. PARP inhibitor resistance: the underlying mechanisms and clinical implications
Platinum resistance follows a similarly tangled pattern. Because platinum drugs and PARP inhibitors sometimes share overlapping vulnerabilities in tumor cells, resistance to one can accompany or predict resistance to the other. The mechanisms behind platinum resistance include changes in DNA damage repair, drug metabolism, cancer stem cell activity, abnormal signaling pathways, and immune evasion, among others.9PubMed Central. Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer Researchers are investigating approaches to overcome or delay both forms of resistance, including epigenetic therapies that aim to reverse the gene-silencing changes cancer cells use to dodge treatment.10PubMed Central. Epigenetic therapies as a promising strategy for overcoming chemoresistance in epithelial ovarian cancer The tumor microenvironment itself also contributes to resistance, as surrounding non-cancer cells, immune cells, and signaling molecules can shield the tumor or alter drug metabolism.11Genes & Diseases. Platinum-resistant ovarian cancer: From mechanisms to treatment strategies
Bevacizumab and Anti-Angiogenic Therapy
Bevacizumab, a drug that blocks the formation of new blood vessels tumors need to grow, was one of the first targeted agents to enter ovarian cancer treatment. Its role has been shaped by several large trials. In a phase III trial involving over 1,800 patients with newly diagnosed advanced ovarian cancer, adding bevacizumab to standard chemotherapy modestly improved progression-free survival, with the greatest benefit seen in patients at high risk for progression. In that high-risk group, median overall survival increased from about 29 months to nearly 37 months with bevacizumab.12PubMed. A phase 3 trial of bevacizumab in ovarian cancer
Bevacizumab has also shown benefit in the harder-to-treat setting of platinum-resistant recurrent disease. In the AURELIA trial, adding bevacizumab to chemotherapy nearly doubled median progression-free survival compared to chemotherapy alone, from about 3.4 months to 6.7 months, and more than doubled the response rate. Overall survival trended in a favorable direction but did not reach statistical significance.13PubMed. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial The drug is now used across multiple settings, including maintenance after first-line treatment and in combination with PARP inhibitors for certain patient groups. Across key trials, median progression-free survival with bevacizumab-containing regimens has been reported as high as 37 months in patients with HRD-positive tumors.14PubMed Central. Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies The most common significant side effect is hypertension.
Antibody-Drug Conjugates for Platinum-Resistant Disease
One of the most noteworthy recent approvals for ovarian cancer is mirvetuximab soravtansine, an antibody-drug conjugate. It works by targeting a protein called folate receptor alpha, which is overexpressed on many ovarian cancer cells. The antibody hunts down the receptor, binds to it, and delivers a potent cell-killing agent directly inside the cancer cell.
In a phase III trial (MIRASOL) of patients with platinum-resistant ovarian cancer whose tumors had high folate receptor alpha expression, mirvetuximab soravtansine outperformed standard chemotherapy across every major outcome. Median overall survival reached about 16.5 months compared to roughly 12.8 months with chemotherapy. The response rate was about 42% versus 16%, and median progression-free survival improved as well.15PubMed. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer An earlier single-arm study (SORAYA) had already demonstrated meaningful antitumor activity and tolerable side effects in a similar population, with a response rate of about 32% and a median response duration of nearly 7 months.16PubMed Central. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
This is a significant step forward because platinum-resistant ovarian cancer has historically been one of the most difficult scenarios to treat. Options were limited and responses short-lived. Having a drug that improves overall survival, not just progression-free survival, in this setting is genuinely unusual.
Immunotherapy Has Been Disappointing So Far
Immune checkpoint inhibitors have transformed treatment in melanoma, lung cancer, and several other tumor types. In ovarian cancer, results have been underwhelming. When used alone, checkpoint inhibitors produce responses in only about 10 to 15% of ovarian cancer patients.17Exploration of Immunology. Research progress of immune checkpoint inhibitors in ovarian cancer Combination strategies, pairing checkpoint inhibitors with chemotherapy, PARP inhibitors, or anti-angiogenic agents, have been studied extensively, but few combinations have produced the kind of dramatic benefit seen in other cancers.
Researchers are now looking beyond checkpoint inhibitors to more engineered immune approaches. CAR-T cell therapy, which has been highly successful against certain blood cancers, is being tested against ovarian tumors in early-phase trials. Several targets on ovarian cancer cells have been identified, including mesothelin, folate receptor alpha, HER2, and MUC16.18PubMed Central. CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now? CAR-NK cell therapies, which use natural killer cells instead of T cells, are also in development. While preclinical results have been encouraging, the immunosuppressive microenvironment of ovarian tumors, their ability to dodge immune attack through antigen escape, and the risk of inflammatory side effects like cytokine release syndrome are real obstacles.19PubMed. Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer These are very early days for cellular immunotherapy in ovarian cancer, and no approved option exists yet.
Surgical Innovations Beyond Standard Debulking
Surgery remains foundational in ovarian cancer treatment, and the goal has always been to remove as much visible tumor as possible, a concept called optimal cytoreduction. Two newer surgical approaches are gaining traction: heated intraperitoneal chemotherapy (HIPEC) and robotic-assisted surgery.
HIPEC involves bathing the abdominal cavity in heated chemotherapy solution immediately after surgical removal of tumors. In a landmark Dutch trial, patients with advanced ovarian cancer who received HIPEC after interval cytoreductive surgery (surgery done partway through chemotherapy) had a median overall survival of nearly 46 months, compared to about 34 months with surgery alone. Recurrence-free survival also improved, and the rate of severe complications was similar between the two groups.20PubMed. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer A meta-analysis of randomized trials confirmed that HIPEC combined with interval cytoreductive surgery significantly improved five-year overall survival and disease-free survival in primary ovarian cancer without a meaningful increase in severe adverse events.21PubMed Central. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials HIPEC is increasingly recognized as effective particularly in patients who have responded to platinum-based chemotherapy, though its adoption varies by institution and not all guidelines endorse it universally.22Gynecologic Oncology. Hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer: A systematic review of phase III randomized controlled trials
Robotic and minimally invasive surgery has also expanded. While open surgery through a large incision remains the guideline-recommended standard, robotic approaches are increasingly used in early-stage disease, where five-year survival already exceeds 90% and quality-of-life considerations carry significant weight.23PubMed. Robotic surgery in ovarian cancer For advanced disease, robotic surgery is being studied in the interval debulking setting, where patients have already received several cycles of chemotherapy before surgery. In a systematic review of these cases, complete removal of all visible tumor was achieved in roughly three-quarters of patients, hospital stays averaged about 2.4 days, and median overall survival ranged from about 40 to 47 months.24PubMed. Robotic interval debulking surgery for advanced epithelial ovarian cancer: current challenge or future direction? A systematic review These numbers are encouraging, though patient selection in surgical studies tends to favor candidates likely to have good outcomes, so comparisons with open surgery need to be interpreted carefully.
Liquid Biopsies and Monitoring Treatment Response
A growing area of research involves tracking ovarian cancer through blood tests rather than tissue biopsies. Circulating tumor DNA (ctDNA), fragments of DNA shed by tumors into the bloodstream, can potentially reveal what the tumor is doing in real time. This approach is far less invasive than taking tissue samples, can be repeated over the course of treatment, and may detect changes in the tumor before they show up on imaging.25PubMed Central. Emerging Applications of Liquid Biopsies in Ovarian Cancer
In ovarian cancer, ctDNA analysis is being studied for diagnosis, prognosis, and predicting whether a given treatment is working.26PubMed Central. Prediction of the treatment response in ovarian cancer: a ctDNA approach It could eventually help oncologists switch treatments earlier when resistance is developing or confirm that a therapy is succeeding without waiting months for imaging. The technology is still largely in the research phase for ovarian cancer, but the trajectory suggests it will become a routine part of care over time.27PubMed Central. The Role of Circulating Tumor DNA in Ovarian Cancer
Early detection is a separate but related frontier. Methylation patterns in cell-free DNA, chemical markers that change when cancer is present, are being investigated as a potential screening tool. Some panels involving large numbers of methylation sites have shown strong performance in research settings, but the evidence is still early. These promising markers need validation in large groups of women with early-stage, asymptomatic disease before they could be considered for clinical use.28PubMed Central. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review
Low-Grade Serous Ovarian Cancer Gets Its Own Playbook
Not all ovarian cancers are the same, and one of the more quietly important advances has been the recognition that low-grade serous ovarian cancer (LGSOC) is a distinct disease requiring its own treatment approach. LGSOC accounts for a small fraction of ovarian cancers but behaves very differently from its high-grade counterpart. It tends to grow slowly, responds poorly to standard platinum-based chemotherapy, and has a unique molecular profile heavy on MAPK pathway alterations (mutations in genes like KRAS, BRAF, and NRAS) and hormone receptor positivity.29PubMed Central. Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease?
This molecular understanding has opened the door to targeted therapies borrowed from other cancer types. MEK inhibitors, which block the MAPK pathway, have shown real efficacy. Trametinib improved progression-free survival in the GOG 281 trial, establishing MEK inhibition as a treatment option for recurrent LGSOC.30PubMed. Repurposing Food and Drug Administration-approved cancer therapies: exploring endocrine and targeted pathways in low-grade serous ovarian cancer treatment Hormonal therapies, similar to those used in breast cancer, have also proven effective in the upfront and recurrent settings, with high response rates and minimal side effects. CDK 4/6 inhibitors, another class of drugs well-established in breast cancer, are being studied in combination with endocrine therapy to enhance responses and address resistance.31PubMed Central. Targeted Therapies in Low-Grade Serous Ovarian Cancers For patients with this subtype, who long had few good options beyond watching their disease slowly progress, these developments are meaningful.
Emerging Drug Targets on the Horizon
Beyond the drugs already approved, several new targets are being explored. One area generating interest is WEE1 kinase inhibition. WEE1 is a protein involved in the cell cycle checkpoint, the internal quality control step a cell goes through before dividing. Blocking WEE1 forces cells with damaged DNA to divide prematurely, which kills them. This approach has shown activity in preclinical models, particularly in cancers with p53 mutations, which account for nearly all high-grade serous ovarian cancers. Early clinical trials have tested WEE1 inhibitors alone and in combination with chemotherapy or other DNA damage pathway drugs, with evidence of both antitumor effect and manageable safety.32PubMed Central. Targeting WEE1 Kinase in Gynecological Malignancies There is also growing interest in combining WEE1 inhibitors with immune checkpoint blockade, based on evidence that WEE1 modulates immune responses within the tumor.
An even more speculative line of research involves the microbiome. Gut, vaginal, and uterine microbial communities appear to influence how patients respond to chemotherapy, anti-angiogenic therapy, and PARP inhibitors. Microbiota and their metabolic byproducts can affect immune responses, drug metabolism, and blood vessel formation around tumors, all of which alter treatment outcomes.33PubMed Central. Potential role of microbiota in ovarian cancer treatment Whether this translates into actionable interventions, such as probiotics or microbiome transplants that improve drug responses, remains to be seen. The research is preliminary but points to an underappreciated factor in why patients with similar tumors sometimes have very different outcomes.
Disparities in Access to Precision Medicine
All of the advances described above depend on one critical step: getting the right test to the right patient at the right time. Genetic testing is the gateway to PARP inhibitors, and biomarker testing determines eligibility for drugs like mirvetuximab soravtansine. Yet access to these tests is uneven. Most individuals with hereditary ovarian cancer syndromes are unaware of their underlying mutations, and racial and ethnic minorities as well as patients with lower socioeconomic status are disproportionately underserved.34PubMed. Genetic Testing for All: Overcoming Disparities in Ovarian Cancer Genetic Testing
Research at hereditary cancer centers has found that minority patients are more likely to come to genetic testing only after a cancer diagnosis rather than based on family history, meaning opportunities for prevention are missed. Among patients found to carry a BRCA1/2 mutation, White patients were more likely to go on to cancer screening and risk-reducing surgery compared to patients of other ethnicities.35PubMed Central. Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center Insurance type also matters. In one study, patients with Medicaid or Medicare were significantly less likely to receive germline or somatic mutation testing compared to those with private insurance, and patients at safety-net hospitals were tested at far lower rates than those at comprehensive cancer centers.36PubMed. Identifying disparities in germline and somatic testing for ovarian cancer
These disparities are not just a fairness issue. They have clinical consequences. A patient who never gets tested for BRCA mutations may never be offered a PARP inhibitor that could meaningfully extend her life. Closing these gaps requires changes at every level, from provider awareness and referral patterns to insurance coverage and community outreach. Precision medicine only works as advertised when it reaches everyone who needs it.